Sichuan Biokin Pharmaceutical Co (688506) Q4 2024 earnings summary

Executive summary

• Achieved net profit attributable to shareholders of RMB 3.71 billion, a turnaround from a loss of RMB 780 million last year, driven by a major licensing deal with BMS for BL-B01D1, including an $800 million upfront payment, marking a significant milestone in global ADC transactions.

• Revenue surged 936.31% year-over-year to RMB 5.82 billion, primarily due to the BMS collaboration and knowledge property income recognition.

• R&D investment reached RMB 1.44 billion, up 93.34% year-over-year, supporting a robust pipeline of 14 clinical-stage innovative drugs and over 70 clinical trials globally.

• The company’s core product BL-B01D1 advanced in multiple global clinical trials and received significant recognition at international conferences.

Financial highlights

• Operating income: RMB 5.82 billion, up 936.31% year-over-year.

• Net profit attributable to shareholders: RMB 3.71 billion, compared to a loss of RMB 780 million last year.

• Basic and diluted EPS: RMB 9.25, compared to -1.95 last year.

• Gross margin for pharmaceutical manufacturing: 95.48%.

• Operating cash flow: RMB 4.06 billion, a significant improvement from negative RMB 615 million last year.

• R&D expenses: RMB 1.44 billion, up 93.34% year-over-year.

Outlook and guidance

• Plans to further expand the global clinical pipeline, focusing on oncology and innovative biologics.

• Will continue to invest heavily in R&D and global clinical development, aiming to launch more products internationally.

• Intends to enhance quality and safety management to meet FDA, EU, and ICH standards, and to strengthen talent and governance.

• No cash dividend, stock dividend, or capital reserve transfer proposed for 2024 due to negative retained earnings at the parent company level.